The Revenue Rises
  • Politics
  • Stocks
  • Business
  • Economy
Trending Now
S&P 500 Earnings for 2025 Q1 — Still...
Money’s Not Leaving the Market — It’s Rotating!
From Oversold to Opportunity: Small Caps on the...
Tariffs and weaker beer demand are weighing on...
Essence Fest leads a summer of events for...
Pullbacks & Reversals: Stocks Setting Up for Big...
S&P 500 Earnings for 2025 Q1 — Still...
Market Signals Align – Is a Bigger Move...
MACD Crossovers: Why Most Traders Get It Wrong
Should You Buy Roblox Stock Now? Key Levels...

The Revenue Rises

  • Politics
  • Stocks
  • Business
  • Economy
Business

Walgreens to go private in roughly $10 billion deal

by admin March 8, 2025
March 8, 2025
Walgreens to go private in roughly $10 billion deal

Struggling drugstore chain Walgreens is going private. 

The company on Thursday said it inked a deal with private equity firm Sycamore Partners that will take it off the public market for an equity value of around $10 billion.

Sycamore will pay $11.45 per share in cash for Walgreens. Shareholders could also receive up to $3 more per share in the future from sales of Walgreens’ primary-care businesses, including Village Medical, Summit Health and CityMD. Walgreens said the total value of the transaction would be up to $23.7 billion when including debt and possible payouts down the line.

Walgreens and Sycamore expect to close the take-private deal in the fourth quarter of this year. Shares of Walgreens jumped more than 5% in after-hours trading on Thursday before being halted.

The historic deal ends Walgreens’ tumultuous run as a public company, which began in 1927. As of Thursday morning, shares of the company were up more than 15% for 2025, but the stock was still down more than 48% for the last year and had fallen 70% for the past three years. 

“While we are making progress against our ambitious turnaround strategy, meaningful value creation will take time, focus and change that is better managed as a private company,” Walgreens CEO Tim Wentworth, who stepped into the role in 2023, said in a release on Thursday. “Sycamore will provide us with the expertise and experience of a partner with a strong track record of successful retail turnarounds.

Stefan Kaluzny, Sycamore’s managing director, said in the release the transaction reflects the firm’s confidence in Walgreens’ “pharmacy-led model and essential role in driving better outcomes for patients, customers and communities.”

Walgreens will maintain its headquarters in Chicago. The company currently has more than 310,000 employees globally and 12,500 retail pharmacy locations across the U.S., Europe and Latin America, according to the release. Walgreens still plans to release its second-quarter earnings on April 8.

Walgreens’s market value reached a peak of more than $100 billion in 2015 as investors gained confidence in its health-care business and expansion plans, making it one of the most prominent American retail companies. 

But the company’s market cap shrank to under $8 billion in late 2024 due to competition from its main rival CVS, grocery chains, big-box retailers and Amazon, along with a slew of challenges. Walgreens has been squeezed by the transition out of the Covid pandemic, pharmacy reimbursement headwinds, softer consumer spending and a troubled push into health care.

Both Walgreens and CVS have pivoted from years of store expansions to shuttering hundreds of retail pharmacy locations across the U.S. to shore up profits. But unlike CVS, which has diversified its business model by offering insurance and pharmacy benefits, Walgreens largely doubled down on its now-flailing retail pharmacy business. 

In October, Walgreens said it plans to close roughly 1,200 of its drugstores over the next three years, including 500 in fiscal 2025 alone. Walgreens has around 8,700 locations in the U.S., a quarter of which it says are unprofitable. The company has also scaled back its push into primary care by cutting its stake in provider VillageMD. 

Walgreens tapped health-care industry veteran Tim Wentworth as its new CEO in late 2023 to help regain its footing. 

The company has reportedly been seen as a potential private equity target in the past. 

In 2019, private equity firm KKR made a roughly $70 billion buyout offer to Walgreens, the Financial Times and Bloomberg reported at the time. 

This post appeared first on NBC NEWS

previous post
S&P 500 Selloff: Bearish Rotation & Key Downside Targets!
next post
Goldman Sachs Kostin Warns of a Potential S&P 500 Correction

Related Posts

Home Depot is buying GMS for about $4.3...

July 1, 2025

There’s been a ‘meaningful shift’ in CEO confidence...

January 16, 2025

Chipotle has been on a hot streak with...

July 26, 2024

DJT shares jump after Trump Media rolls out...

August 5, 2024

Chase Bank is referring check fraud ‘glitch’ incidents...

September 10, 2024

Albertsons sues Kroger after judge rules against grocery...

December 12, 2024

Walmart-owned Sam’s Club tests a future without checkout...

October 10, 2024

Nationwide coordinated retail crime crackdown results in hundreds...

June 5, 2025

United Airlines adds Thailand, Vietnam and Australia flights...

April 3, 2025

U.S. airlines cool hiring after adding 194,000 employees...

September 9, 2024

    Become a VIP member by signing up for our newsletter. Enjoy exclusive content, early access to sales, and special offers just for you! As a VIP, you'll receive personalized updates, loyalty rewards, and invitations to private events. Elevate your experience and join our exclusive community today!


    By opting in you agree to receive emails from us and our affiliates. Your information is secure and your privacy is protected.

    Recent Posts

    • S&P 500 Earnings for 2025 Q1 — Still Overvalued
    • Money’s Not Leaving the Market — It’s Rotating!
    • From Oversold to Opportunity: Small Caps on the Move
    • Tariffs and weaker beer demand are weighing on Modelo owner Constellation Brands
    • Essence Fest leads a summer of events for Black entrepreneurs galvanized by economic uncertainty

    Popular Posts

    • 1

      Polls show some good early signs for Kamala Harris

      July 26, 2024
    • 2

      Solana and Cardano: Solana is waiting for a new impulse

      July 18, 2024
    • 3

      The presidential race shifts — modestly, so far — toward Harris

      August 6, 2024
    • 4

      Donald Trump’s imaginary and frightening world

      September 23, 2024
    • 5

      A Harris-Trump race would pit ex-prosecutor vs. recently convicted felon

      July 22, 2024

    Categories

    • Business (729)
    • Economy (975)
    • Politics (873)
    • Stocks (867)
    • About us
    • Privacy Policy
    • Terms & Conditions

    Disclaimer: therevenuerises.com, its managers, its employees, and assigns (collectively “The Company”) do not make any guarantee or warranty about what is advertised above. Information provided by this website is for research purposes only and should not be considered as personalized financial advice. The Company is not affiliated with, nor does it receive compensation from, any specific security. The Company is not registered or licensed by any governing body in any jurisdiction to give investing advice or provide investment recommendation. Any investments recommended here should be taken into consideration only after consulting with your investment advisor and after reviewing the prospectus or financial statements of the company.

    Copyright © 2024 The Revenue Rises. All Rights Reserved.